Mycovia Pharmaceuticals has partnered with Jiangsu Hengrui Medicine to develop and commercialise its investigational drug VT-1161 (otesaconazole) in China.

Under an agreement signed by the companies, the VT-1161 treatment for recurrent vulvovaginal candidiasis (RVVC), onychomycosis and invasive fungal infection will be developed and commercialised in areas such as mainland China, Hong Kong, Macau and Taiwan.

At present, Mycovia is carrying out global Phase III trials of the drug in women with RVVC to support marketing applications in the US, the EU and Japan. VT-1161 is claimed to have fewer side effects and improved potency compared to existing treatment options.

Last year, NovaQuest Capital Management formed Mycovia to advance the drug globally.

NovaQuest capital management partner Patrick Jordan said: “In addition to the treatment of RVVC, early research suggests that VT-1161 has strong potential in the fight against other fungal infections, including azole-resistant fungal infections, which pose an increasing threat to public health in China and across the globe.

“With Hengrui’s expertise and commitment bolstering Mycovia’s passion and focus, VT-1161 is well positioned for development and commercialisation in one of the world’s largest and fastest growing markets.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Under the partnership, Mycovia will receive development funding, regulatory milestones, sales milestones and royalties on the net sales of VT-1161 in China.

Hengrui Medicine board chairman Piaoyang Sun said: “This partnership with Mycovia provides us with an opportunity to better serve the antifungal medical needs for patients in China across a broad spectrum of infections, including superficial and invasive infections.”

The drug received FDA Qualified Infectious Disease Product and Fast-Track designations to support its potential as the first treatment approved by the agency for the treatment of RVVC.